Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.16) by 56.25 percent. This is a 125.93 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $211.572 million which beat the analyst consensus estimate of $195.004 million by 8.50 percent. This is a 21.48 percent increase over sales of $174.159 million the same period last year.